MEDI 0618
Alternative Names: MEDI-0618Latest Information Update: 25 Oct 2024
At a glance
- Originator AstraZeneca
- Class Analgesics; Monoclonal antibodies
- Mechanism of Action PAR 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Migraine
- Phase I Pain
Most Recent Events
- 07 Oct 2024 Phase-II clinical trials in Migraine (Treatment-experienced) in USA, Czech Republic, Denmark, Germany, Hungary, Netherlands, Italy, Poland, Spain (Parenteral) (NCT06602479)
- 19 Sep 2024 AstraZeneca plans a phase II trial for Migraine (Treatment experienced) in USA, Czech Republic, Denmark, Germany, Hungary, Italy, Netherlands, Poland, Spain (SC) (NCT06602479)
- 12 Dec 2023 AstraZeneca completes a Phase I development in Pain (In volunteers) is ongoing in Germany (SC) (IV) (NCT05714254)